Relay Therapeutics, Inc.
RLAY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $1 |
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | -91.2% | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -11,203.1% | -1,089.5% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -10,395.1% | -1,003.6% | – |
| EPS Diluted | -0.43 | -0.41 | -0.46 | -0.45 |
| % Growth | -4.9% | 10.9% | -2.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |